Analysis Of Income And Expense [Abstract]

Biofrontera AG - Filing #6520750

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Interest income	—	—	21,000 EUR	—	—	—	1,000 EUR	—	—	—
Revenue	—	—	32,249 EUR	—	—	—	25,738 EUR	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	7,846 EUR	—	—	—	7,128 EUR	—	—	—
Other finance income	—	—	7,264 EUR	—	—	—	44,172 EUR	—	—	—
Interest expense	—	—	15,000 EUR	—	—	—	163,000 EUR	—	—	—
Expenses by nature [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense	—	—	791,000 EUR	—	—	—	746,000 EUR	—	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	1,000 EUR	—	—	—	0 EUR	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 EUR	1,000 EUR	368,000 EUR	0 EUR	369,000 EUR	0 EUR	44,166 EUR	44,166 EUR	0 EUR	0 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	368,000 EUR	—	—	—	44,166 EUR	—	—	—